A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00241449. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-blind, Randomized, Multicentre Trial Comparing the Efficacy and Tolerability of 250mg of Faslodex (Long Acting ICI 182,780) With 20mg of Nolvadex (Tamoxifen) in Postmenopausal Women With Advanced Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to compare the efficacy of Faslodex (fulvestrant) to Nolvadex (tamoxifen) as first-line treatment for postmenopausal women with advanced breast cancer. Patients will be treated until disease progression or until the investigator has determined that treatment is not in the best interest of the patient, whichever occurs first.
Study identification
- NCT ID
- NCT00241449
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 51 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 1998 (Type not available)
- Primary completion
- Mar 2007 (Actual)
- Completion
- Jan 2012 (Actual)
- Last update posted
- Jun 6, 2012
1998 – 2012
United States locations
- U.S. sites
- 24
- U.S. states
- 17
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Little Rock | Arkansas | — | — |
| Research Site | Fountain Valley | California | — | — |
| Research Site | La Jolla | California | — | — |
| Research Site | Orange | California | — | — |
| Research Site | Washington D.C. | District of Columbia | — | — |
| Research Site | Venice | Florida | — | — |
| Research Site | Decatur | Georgia | — | — |
| Research Site | Chicago | Illinois | — | — |
| Research Site | Mason City | Iowa | — | — |
| Research Site | Shreveport | Louisiana | — | — |
| Research Site | Gloucester | Massachusetts | — | — |
| Research Site | Detroit | Michigan | — | — |
| Research Site | Voorhees Township | New Jersey | — | — |
| Research Site | Columbus | Ohio | — | — |
| Research Site | Meadowbrook | Pennsylvania | — | — |
| Research Site | Providence | Rhode Island | — | — |
| Research Site | Austin | Texas | — | — |
| Research Site | Galveston | Texas | — | — |
| Research Site | Houston | Texas | — | — |
| Research Site | San Antonio | Texas | — | — |
| Research Site | Temple | Texas | — | — |
| Research Site | Richmond | Virginia | — | — |
| Research Site | Lacey | Washington | — | — |
| Research Site | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 115 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00241449, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 6, 2012 · Synced Nov 15, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.